Key facts
- Hygieia Pharmaceuticals’s last known valuation is $173.3M (Feb 2026).
- It has raised $28.0M; the latest was Merger/Acquisition ($173.3M) in Feb 2026.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Hygieia Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Hygieia Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hygieia Pharmaceuticals
Operator of a siRNA drug development platform designed to treat cancer. The company focuses on the research and development of small interfering RNA drugs for chronic disease treatment that can regulate the expression of genes, thereby enabling potential inhibition of cancer-related genes.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 60
- Website
- hygieiapharma.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Hygieia Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hygieia Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hygieia Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.